Relapse-free survival after URD HCT: multivariate analysis
| All samples . | RR of relapse or death . | 95% CI . | P . |
|---|---|---|---|
| KIR genotype | |||
| B/x (compared with A/A) | 0.70 | 0.55-0.88 | .002 |
| Transplant group | |||
| HLA mismatched/KIR-ligand match (compared with 10/10 HLA matched) | 1.21 | 0.95-1.54 | .13 |
| HLA mismatched/KIR-ligand mismatch (compared with10/10 HLA matched) | 1.65 | 1.22-2.23 | .001 |
| Disease status | |||
| Intermediate (compared with early) | 1.41 | 0.99-2.02 | .06 |
| Advanced (compared with early) | 2.17 | 1.58-2.99 | <.001 |
| Age (categoric) | .03 | ||
| Karnofsky performance status | .01 | ||
| Time from diagnosis to transplantation, per year | 0.88 | 0.77-1.02 | .08 |
| Nonwhite | 1.34 | 0.95-1.88 | .10 |
| All samples . | RR of relapse or death . | 95% CI . | P . |
|---|---|---|---|
| KIR genotype | |||
| B/x (compared with A/A) | 0.70 | 0.55-0.88 | .002 |
| Transplant group | |||
| HLA mismatched/KIR-ligand match (compared with 10/10 HLA matched) | 1.21 | 0.95-1.54 | .13 |
| HLA mismatched/KIR-ligand mismatch (compared with10/10 HLA matched) | 1.65 | 1.22-2.23 | .001 |
| Disease status | |||
| Intermediate (compared with early) | 1.41 | 0.99-2.02 | .06 |
| Advanced (compared with early) | 2.17 | 1.58-2.99 | <.001 |
| Age (categoric) | .03 | ||
| Karnofsky performance status | .01 | ||
| Time from diagnosis to transplantation, per year | 0.88 | 0.77-1.02 | .08 |
| Nonwhite | 1.34 | 0.95-1.88 | .10 |